InterMune's Esbriet gets OK from EU CHMP: launch expected 3Q11
This article was originally published in Scrip
Executive Summary
InterMune's Esbriet (pirfenidone) received a positive opinion by the EU's Committee for Medicinal Products for Human Use (CHMP), the first European approval for any drug to treat mild-to-moderate idiopathic pulmonary fibrosis (IPF). In a conference call, the company CEO and President, Dan Welch, said that the company anticipated a price band for the product of $40,000-45,000 and that the product would be launched in the five largest European national markets – Germany, France, Italy, Spain and the UK – by mid 2012, with the first launch in Germany scheduled for the third quarter of 2011.